Phd in NETWORK ONCOLOGY AND PRECISION MEDICINE

Position
Physician at Department of Pediatric Hematology and Oncology - IRCCS Bambino Gesù Children's Hospital.

Work experience
From April 2022: Physician at Department of Pediatric Hematology and Oncology - IRCCS Bambino Gesù Children's Hospital, Director: Prof. Franco Locatelli.
From February 2019: Freelance contract Doctor at Day Hospital of Bone Marrow Transplant Unit, Department of Pediatric Hematology and Oncology - IRCCS Bambino Gesù Children's Hospital.
From December 2018: Freelance contract Doctor at Department of Pediatric Hematology and Oncology - IRCCS Bambino Gesù Children's Hospital.
From May to August 2018: Resident at Department of Pediatric Hematology and Oncology at "A. Cao" Microcitemico Hospital - Cagliari, Director: Dr. Rosa Maria Mura.
From March 2016 to March 2017 and from November 2017 to May 2018: Resident at S.C. Pediatric Oncology – Fondazione IRCCS Istituto Nazionale dei Tumori of Milan, Director: Maura Massimino.

Education and training
March 2012: Medical and Surgical License (register number 1151) to Ordine dei Medici Chirurghi e degli Odontoiatri della Provincia di Oristano.
July 2012: Medical and Surgical Degree, Final grades 110/110 summa cum laude (the highest possible grade in the Italian system), University of Cagliari, Faculty of Medicine and Surgery.
July 2004: High School Diploma, Final grade 100/100 (the highest possible grade in the Italian system), Scientific High School "A. Volta" - Ghilarza (OR), Sardinia, Italy.

Skills

·       clinical care to patients undergoing hematopoietic stem cell transplantation for malignant and non-malignant diseases at the Bone Marrow Transplant Unit, both in the pre-transplant screening and in the post-transplant follow-up.

·       clinical care to children undergoing CAR T-cell therapy for Neuroblastoma.

·       clinical care to patients involved in clinical trials of gene therapy and/or genome editing.

Research project
Improve knowledge about cancer hereditary predisposition in pediatric and adolescent cohorts and provide new insights that may be useful to further improve Cancer Predisposition Syndromes (CPS) diagnosis, treatment, surveillance, and follow-up.
In particular: discover potential correlations between germline genetic variation and somatic mutation profile; identify new molecular alterations associated with CPS by studying the variants of uncertain significance (VUS) and defining their pathogenetic role in performing functional studies; discover potential new diagnostic and therapeutic targets; improve epidemiological data on CPS in children and adolescents with cancer.

Clinical trial
Participation as sub-investigator in the following research clinical trials:

·       Phase I clinical trial on the use of fresh, allogeneic, second-generation CD19-CAR T cells for treatment of children and young adult with relapsed/refractory B-cell Acute Lymphoblastic Leukemia. (Protocol code: AlloCAR). PI: Prof. Franco Locatelli.

·       Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric/young adult patients affected by relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/Lymphoma. (Protocol code: CD7-CAR01). PI: Prof. Franco Locatelli.

·       INTERNATIONAL MULTICENTER, OPEN-LABEL CLINICAL TRIAL FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA IN CHILDREN AND ADOLESCENTS. (Protocol code: AIEOP-BFM-AML 2020). PI: Prof. Franco Locatelli.

·       A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML. (Protocol code: ITCC-101/APAL2020D). PI: Prof. Franco Locatelli.

·       A Randomised, Open-label, Controlled, Multicentre, Phase 2 Trial of First-line Treatment With Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Paediatric Participants With Steroid-refractory Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation (BALDER Trial) (Protocol code: MC-MSC.2/aGvHD). PI: Prof. Franco Locatelli.

·       Longterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product. (Protocol code: LTF-304). PI: Prof. Franco Locatelli.

·       A Long-term Follow-up Study of Subjects With β-thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001). (Protocol code: VX18-CTX001-131). PI: Prof. Franco Locatelli.

·       A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease. PI: Prof. Franco Locatelli.